Latest Disease-modifying antirheumatic drug Stories
Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active
New results from the National Health and Wellness Survey show few eligible patients are using biologic treatments. New York, NY (PRWEB) September 14, 2013
This means that 320 million people - 40% of Europe's population - who could benefit from treatment with disease modifying drugs (DMARDs) would struggle to get access to them, say the researchers.
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.